DOCSLIB.ORG

| Hai Laila a Ta a Un Mai Mult Mai Mult

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

|HAI LAILA ATA A US009732081B2UN MAI MULT MAI MULT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,732 ,081 B2 Patil et al. (45 ) Date of Patent: Aug . 15 , 2017 ( 54) 1 ,6 -DIAZABICYCLO [3 , 2 , 1 ] OCTAN - 7 -ONE (51 ) Int. CI. DERIVATIVES AND THEIR USE IN THE C07D 471 /08 ( 2006 .01 ) TREATMENT OF BACTERIAL INFECTIONS A61K 31/ 439 (2006 .01 ) A61K 31/ 4545 ( 2006 .01 ) A61K 31 / 496 ( 2006 . 01 ) ( 71 ) Applicant: WOCKHARDT LIMITED , A61K 31 / 55 ( 2006 .01 ) Aurangabad ( IN ) C07D 487 / 08 ( 2006 .01 ) A61K 31/ 407 (2006 . 01 ) ( 72 ) Inventors : Vijaykumar Jagdishwar Patil, Solapur A61K 31/ 546 ( 2006 .01 ) ( IN ) ; Ravikumar Tadiparthi, A61K 45 / 06 ( 2006 .01 ) Auranagabad ( IN ) ; Bharat Dond , C07C 211/ 63 ( 2006 . 01 ) Aurangabad ( IN ) ; Amol Kale , ( 52 ) U . S . CI. Aurangabad ( IN ) ; Loganathan CPC . .. .. C070 471 /08 (2013 .01 ) ; A61K 31/ 407 Velupillai , Aurangabad ( IN ) ; Deepak ( 2013 .01 ) ; A61K 31/ 439 ( 2013 . 01 ) ; A61K Dekhane , Maharashtra Pune ( IN ) ; 31/ 4545 (2013 . 01 ) ; A61K 31/ 496 ( 2013. 01 ) ; Satish Shrimant Birajdar , Pin - O Latur A61K 31/ 546 ( 2013 .01 ) ; A61K 31/ 55 ( IN ) ; Mohammad Usman Shaikh , ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; C07C Shrirampur ( IN ) ; Sushilkumar 211/ 63 ( 2013 .01 ) ; CO7D 487/ 08 ( 2013. 01 ) Maurya , Maharashtra Aurangabad ( IN ) ; (58 ) Field of Classification Search Piyush Ambalal Patel, Gujarat Anand CPC . .. .. .. C07D 471 /08 ( IN ) ; Prasad Dixit, Maharashtra See application file for complete search history . Aurangabad ( IN ) ; Mangesh Pawar , Maharashtra Aurangabad (IN ) ; Mahesh (56 ) References Cited Vithalbhai Patel , Aurangabad ( IN ) ; Sachin Bhagwat, M . S . Aurangabad U . S . PATENT DOCUMENTS ( IN ) 2013 /0225554 AL 8 /2013 Maiti et al. ( * ) Notice: Subject to any disclaimer, the term of this Primary Examiner — Bruck Kifle patent is extended or adjusted under 35 (74 ) Attorney , Agent, or Firm — Bio Intellectual Property U . S . C . 154 (b ) by 0 days. Services LLC (Bio IPS ) ; O . (Sam ) Zaghmout (21 ) Appl. No. : 15/ 062, 148 (57 ) ABSTRACT Compounds of Formula ( I ) , their preparation and use in ( 22 ) Filed : Mar. 6 , 2016 preventing or treating bacterial infections are disclosed . (65 ) Prior Publication Data US 2016 / 0213655 A1 Jul . 28 , 2016 Formula ( I) Related U . S . Application Data R3 -Z (63 ) Continuation of application No . 14 / 365 , 064 , filed as R2 application No . PCT / IB2013 /053092 on Apr. 19 , 2013 . N - R1 ( 30 ) Foreign Application Priority Data Aug. 25 , 2012 ( IN ) .. .. 2471 /MUM / 2012 36 Claims, No Drawings US 9 , 732 ,081 B2 1 , 6 -DIAZABICYCLO ( 3 , 2 , 1 ] OCTAN - 7 -ONE or a stereoisomer or a pharmaceutically acceptable salt DERIVATIVES AND THEIR USE IN THE thereof ; TREATMENT OF BACTERIAL INFECTIONS wherein : R , is : CROSS -REFERENCE TO RELATED ( a ) SO3M , APPLICATIONS ( b ) SO2NH2, ( C ) PO , M , This application is a Continuation of U . S . application Ser . ( d ) CH , COOM , No. 14 / 365 , 064, filed Jun . 12 , 2014 , now pending, which ( e ) CF , COOM , entered the National Phase of Serial No. PCT/ IB2013 / 10 ( f ) CHFCOOM , or 053092 , filed Apr. 19 , 2013 , which claims priority to Indian ( g ) CF3 ; Application No . IN2012MU2471A , filed Aug. 25 , 2012 . The M is hydrogen or a cation ; entire disclosure of these prior applications are hereby R2 is : incorporated by reference . ( a ) hydrogen , 15 ( b ) (CH ) n - R3, or FIELD OF THE INVENTION ( c ) COOR3, The invention relates to nitrogen containing compounds , n is 0 , 1 or 2 ; use of these compounds as antibacterial agents , composi Rz is : tions comprising them and processes for their preparation . ( a ) hydrogen , 20 ( b ) C . - C . alkyl optionally substituted with one or more BACKGROUND OF THE INVENTION substituents independently selected from halogen , OR , CN , COORS, CONRR7, NR R7, NR , COR , , Emergence of bacterial resistance to known antibacterial NR , CONRGR7, heterocyclyl , heteroaryl , cycloalkyl or agents is becoming a major challenge in treating bacterial aryl, infections. One way forward to treatat bacterial infectionsinfections , and 25 ( c ) CN , especially those caused by resistant bacteria , is to develop ( d ) NRGR7, newer antibacterial agents that can overcome the bacterial ( e ) CONRR , resistance . Coates et al. (Br . J . Pharmacol . 2007 ; 152 ( 8 ) , ( 1 ) NHCONRR , 1147 - 1154 ) have reviewed novel approaches to developing ( g ) aryl optionally substituted with one or more substitu new antibiotics . However , the development of new antibac - 30 ents independently selected from C . - C . alkyl, OR , terial agents is a challenging task . For example , Gwynn et al. NR R7, halogen , CN , CONRGR7, SO2- alkyl, SO2- aryl, ( Annals of the New York Academy of Sciences, 2010 , 1213 : OSO2- alkyl , OSO2- aryl, or NHCONRGR7, 5 - 19 ) have reviewed the challenges in the discovery of ( h ) heterocyclyl optionally substituted with one or more antibacterial agents . substituents independently selected from C - C . alkyl, Several antibacterial agents have been described in the 35 OR . , NR R7, halogen , CN , CONRGR7, SO2- alkyl, prior art ( for example , see PCT International Application SO2- aryl, OSO2- alkyl , OSO2- aryl, or NHCONRGR7, Nos. PCT /US2010 / 060923 , PCT / EP2010 / 067647 , PCT / ( i) heteroaryl optionally substituted with one or more US2010 /052109 , PCT/ US2010 /048109 , PCT/ GB2009 / substituents independently selected from C1- C6 alkyl, 050609 , PCT /EP2009 /056178 and PCT/ US2009 /041200 ) . OR5, NR R7, halogen , CN , CONRGR7, SO2 - alkyl, However , there remains a need for potent antibacterial 40 SO2- aryl , OSO2- alkyl, OSO2- aryl, or NHCONRR7, agents for preventing and / or treating bacterial infections, (j ) cycloalkyl optionally substituted with one or more including those caused by bacteria that are resistant to substituents independently selected from C , - C alkyl , known antibacterial agents . ORs, NR R7, halogen , CN , CONRGR7, SO2- alkyl , The inventors have surprisingly discovered nitrogen con SO2- aryl , OSO , - alkyl , OSO , - aryl, or NHCONRR , , taining compounds with antibacterial properties . 45 ( k ) cycloalkyl substituted with C1- C6 alkylwherein C , - C6 alkyl is further substituted with one or more substitu SUMMARY OF THE INVENTION ents independently selected from OR5 , NRR , , halo gen , CN , or CONRGR7 , or Accordingly there are provided nitrogen containing com ( 1) ORS; pounds, methods for preparation of these compounds, phar - 50 R4 18 : maceutical compositions comprising these compounds, and ( a ) hydrogen , method for preventing or treating bacterial infection in a ( b ) C . - C . alkyl optionally substituted with one or more subject using these compounds . substituents independently selected from halogen , OR5, In one general aspect , there are provided compounds of CN , COOR , CONRGR7, NR R7, NR , CORg, hetero Formula ( I ) : 55 cyclyl , heteroaryl, cycloalkyl or aryl, ( c ) aryl optionally substituted with one or more substitu ents independently selected from C . - C . alkyl, OR , Formula ( I) NR R7, halogen , CN , CONRR7, SO2- alkyl, SO2- aryl, OSO , - alkyl, OSO , - aryl, or NHCONRR , 60 ( d ) heterocyclyl optionally substituted with one or more R3 substituents independently selected from C , - C . alkyl, Z- ORs, NR R7, halogen , CN , CONRGR7, SO2- alkyl, R2 SOZ- aryl, OSO2 - alkyl, OSO2- aryl, or NHCONRGR7, ( e ) heteroaryl optionally substituted with one or more DARI 65 substituents independently selected from C . - C . alkyl, ORs, NR R7, halogen , CN , CONRGR7, SO2- alkyl , SO2- aryl , OSO2- alkyl , OSO2- aryl, or NHCONRGR7, or US 9 ,732 ,081 B2 ( f) cycloalkyl optionally substituted with one or more thereof, and ( b ) at least one beta - lactamase inhibitor selected substituents independently selected from C , - C6 alkyl, from sulbactam , tazobactam , clavulanic acid , or a pharma OR5, NR R7, halogen , CN , CONRR7, SO2- alkyl, ceutically acceptable derivative thereof. SO2- aryl, OSO2- alkyl, OSO2 - aryl, or NHCONR Rz; In another general aspect, there are provided pharmaceu R , and R , are each independently : 5 tical compositions comprising : ( a ) a compound of Formula ( a ) hydrogen , or ( I ) , or a stereoisomer or a pharmaceutically acceptable salt ( b ) C -C6 alkyl optionally substituted with one or more thereof, and ( b ) at least one antibacterial agent or a phar substituents independently selected from halogen , CN , maceutically acceptable derivative thereof. CONRR , NR R7, heterocyclyl, heteroaryl, In another general aspect , there are provided pharmaceu cycloalkyl or aryl; 10 tical compositions comprising : ( a ) a compound of Formula Ro and R , are each independently : ( I ) , or a stereoisomer or a pharmaceutically acceptable salt ( a ) hydrogen , thereof, ( b ) at least one beta - lactamase inhibitor selected (b ) C . - Cô alkyl optionally substituted with one or more from sulbactam , tazobactam , clavulanic acid , or a pharma substituents independently selected from halogen , OR , ceutically acceptable derivative thereof , and ( c ) at least one CN , COORS, CONR = R3, NR =Rs , NR ,CORg , hetero - 15 antibacterial agent or a pharmaceutically acceptable deriva cyclyl , heteroaryl , cycloalkyl or aryl, tive thereof. ( c ) aryl optionally substituted with one or more substitu - In another general aspect, there is provided a method for ents independently selected from C , - C , alkyl, OR5 , preventing or treating bacterial infection in a subject , said NR =Rg , halogen , CN , CONR Rg, SO2- alkyl, SO2- aryl, method comprising administering to
Recommended publications
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT

    WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
  • WO 2010/025328 Al

    WO 2010/025328 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
  • Computational Antibiotics Book

    Computational Antibiotics Book

    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept

    Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept

    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 2 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • The Antibiotics Composition Comprising Beta-Lactam

    The Antibiotics Composition Comprising Beta-Lactam

    (19) & (11) EP 2 062 581 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 31/545 (2006.01) A61K 31/546 (2006.01) A61K 31/43 (2006.01) A61K 31/431 (2006.01) (2006.01) (2006.01) (21) Application number: 07785338.0 A61K 31/424 A61K 31/7036 A61K 47/18 (2006.01) A61K 47/12 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.08.2007 A61K 47/02 A61K 47/04 A61K 9/08 (2006.01) A61K 9/19 (2006.01) A61K 9/72 (2006.01) A61P 31/04 (2006.01) A61P 31/00 (2006.01) (86) International application number: PCT/CN2007/002438 (87) International publication number: WO 2008/025226 (06.03.2008 Gazette 2008/10) (84) Designated Contracting States: (71) Applicant: Tianjin Hemey Bio-Tech Co., Ltd. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tianjin 300457 (CN) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: ZHANG, Hesheng Designated Extension States: Tianjin 300457 (CN) AL BA HR MK RS (74) Representative: Hryszkiewicz, Danuta et al (30) Priority: 25.08.2006 CN 200610015437 Kancelaria Patentowa ul. Jana z Kolna 38 PL-75-204 Koszalin (PL) (54) THE ANTIBIOTICS COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTICS AND IONIC CHELATING AGENTS (57) The antibiotics composition comprising at least tors and buffers simultaneously. The composition can be one of beta-lactam antibiotics and at least one of ionic formulated with at least one of aminoglycoside antibiotics chelating agents used for inhibiting particulate formation, into solution for controlling microbial infection in a con- further comprising at least one of beta-lactamase inhib- tainer.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 8 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • 抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定）

    抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定）

    抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定） 略 語 一般名（慣用名） 開発番号 略 語 一般名（慣用名） 開発番号 BLs ● β-ラクタム系 CEC cephacetrile （β-lactams） CEPR cephapirin PCs ペニシリン系 CER cephaloridine （penicillins） CET cephalothin ABPC ampicillin CEZ cefazolin ACPC ciclacillin CFCL cefclidin E1040 AMPC amoxicillin CFDC cefiderocol S-649266 APPC apalcillin PC-904 CFLP cefluprenam E1077 ASPC aspoxicillin TA-058 CFPM cefepime BMY-28142 BAPC bacampicillin CFS cefsulodin SCE-129 CBPC carbenicillin CFSL cefoselis FK037 CFPC carfecillin CMD cefamandole CIPC carindacillin CMX cefmenoxime SCE-1365 DMPPC methicillin CPIZ cefpimizole AC-1370 IPABPC hetacillin CPM cefpiramide SM-1652 LAPC lenampicillin KBT-1585 CPR cefpirome HR-810 MCIPC cloxacillin CPZ cefoperazone T-1551 MDIPC dicloxacillin CTM cefotiam SCE-963 MFIPC flucloxacillin CTRX ceftriaxone Ro13-9904 MPC mecillinam CTX cefotaxime MPIPC oxacillin CTZ ceftezole MZPC mezlocillin CXM cefuroxime NFPC nafcillin CZON cefuzonam L-015 PCG benzylpenicillin CZOP cefozopran SCE-2787 （penicillin G） CZX ceftizoxime PCV phenoxymethyl penicillin SBT/CPZ sulbactam/cefoperazone （penicillin V） TAZ/CTLZ tazobactam/ceftolozane MK-7625A PEPC phenethicillin （経口用） PIPC piperacillin CCL cefaclor PMPC pivmecillinam CDTR-PI cefditoren pivoxil ME-1207 PPPC propicillin CDX cefadroxil BL-S578 PVPC pivampicillin CED cefradine SBPC sulbenicillin CEG cephaloglycin SBTPC sultamicillin CEMT-PI cefetamet pivoxil Ro15-8075 TAPC talampicillin CETB ceftibuten 7432-S TIPC ticarcillin CEX cephalexin ABPC/ CFDN cefdinir FK482 MCIPC ampicillin/cloxacillin